This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 549.35% and 487.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -16.67% and 23.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 0.70% and 30.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
by Zacks Equity Research
Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Cigna Group (CI) This Year?
by Zacks Equity Research
Here is how Cigna (CI) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 8th
by Zacks Equity Research
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
5 Small-Cap Stocks to Play the January Effect
by Sweta Killa
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
New Strong Buy Stocks for January 8th
by Zacks Equity Research
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 13.16% and 5.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -15.91% and 6.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.